FDA-Approved Biomarker Panels: The Good, The Bad, and The Ugly

Here at Amplion we are currently thinking very hard about how to represent in BiomarkerBase the ways in which emerging biomarkers are naturally grouping into panels, based on how they are used in clinical trials, described in the literature, and appear in clinical tests.

Academic and Commercial Institutions Team Up to Enrich Variant Analysis

by John Audette | Feb 24, 2015 | Development, News

In a move that directly addresses the problems plaguing the ability to conduct statistically-driven analysis of clinical genomic data (as described in the previous post), Qiagen and LabCorp have teamed up with multiple prestigious academic institutions to form the Allele Frequency Community.

"As I lay dying" - A Powerful Personal Exhortation

This moving opinion piece in the LA Times was just shared with me by Adam Carroll (our CSO and co-founder), which was written by a distinguished foreign correspondent, Laurie Becklund, who just died of breast cancer.

Linking Data Silos is a Major Key to Clinical Genomics

by John Audette | Feb 06, 2015 | Development, News

Part of President Obama's "precision medicine" initiative is the characterization of the genomes of one million American volunteers. The proposal includes characterizing several hundred thousand new participants, and connecting the data with genetic information from hundreds of thousands of ...

Notes from the Personalized Medicine World Conference

by John Audette | Feb 02, 2015 | Marketing, News, Regulation

I was in Silicon Valley last week for the seventh annual Personalized Medicine World Conference, and all the buzz was around clinical applications for NGS. While there have clearly been significant advances in the field, it is also clear that we are a long way off from NGS becoming a routine part ...




Pharmacovigilance and Safety Biomarkers

New Call-to-action

Subscribe for Updates

Download our Free IVD Trends Report